KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Net Cash Flow (2018 - 2025)

Vir Biotechnology (VIR) has disclosed Net Cash Flow for 8 consecutive years, with $61.8 million as the latest value for Q4 2025.

  • Quarterly Net Cash Flow rose 13.7% to $61.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$77.6 million through Dec 2025, down 235.23% year-over-year, with the annual reading at -$77.6 million for FY2025, 235.23% down from the prior year.
  • Net Cash Flow hit $61.8 million in Q4 2025 for Vir Biotechnology, up from -$127.0 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $690.9 million in Q2 2022 to a low of -$542.7 million in Q3 2022.
  • Historically, Net Cash Flow has averaged -$10.5 million across 5 years, with a median of -$40.6 million in 2021.
  • Biggest YoY gain for Net Cash Flow was 452.44% in 2022; the steepest drop was 1816.04% in 2022.
  • Year by year, Net Cash Flow stood at -$364.2 million in 2021, then surged by 68.15% to -$116.0 million in 2022, then crashed by 81.95% to -$211.1 million in 2023, then soared by 125.76% to $54.4 million in 2024, then increased by 13.7% to $61.8 million in 2025.
  • Business Quant data shows Net Cash Flow for VIR at $61.8 million in Q4 2025, -$127.0 million in Q3 2025, and -$61.7 million in Q2 2025.